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Fever is indisputably one of the most common symptoms triggering the quest 
for health care provision, globally, but particularly so in low and middle-income 
countries (LMIC), where infectious diseases remain highly prevalent, and where 
fever is a well-known cause of premature mortality. The epidemiology of fever is 
highly variable, with a myriad of different potential etiologies, and heavily 
dependent on a variety of parameters, including among others, the age of the 
individual affected, the presence of concomitant conditions, the geographical 
distribution and circulation of different pathogens, and the implementation of 
different control measures destined to decrease the risk of certain diseases[1]. 
In outpatient clinics throughout the world, clinicians visiting sick febrile patients 
are faced with two diagnostic dilemmas that are at the basis of their 
management decisions: 1) Is this fever caused by a pathogen that requires 
antibiotic treatment?  and 2) Is this patient at risk of progressing to a life-
threatening disease? In high-income countries, the answer to both questions 
can partially be provided by thorough diagnostic investigations that may be able 
to identify the underlying cause, and stratify the risk and guide management. In 
LMIC, however, access to the health system is much more limited, diagnostic 
tools remain scarce, and management decisions -by definition more subjective- 
may have much more profound implications. Thus, identifying mechanisms 
which could help frontline clinicians in these settings reliably answer those two 
questions could significantly improve their diagnostic and therapeutic approach, 
and as a result, the well-being and survival probabilities of their patients.  
The answer to the first question presupposes that fever arises as the direct 
response of the human host to the infection caused by a single pathogen, and 
that as a result, identifying that microorganism will determine a binary decision 
that can be summarized as follows: a) Bacterial: antibiotics required; b) Non-
bacterial: no antibiotics required. However, in the last years, increasing 
evidence has arisen to counteract the oversimplification of such an approach. 
First, the assumption that all outpatient infections of presumed bacterial origin 
require the use of antibiotics is not necessarily true, as many of them can be 
managed in a conservative manner[2, 3]. Second, large multicenter studies 
thoroughly investigating the underlying etiology of fever, or other major 











evidenced the paucity of pure single-pathogen infections, pointing instead 
towards a not uncommon scenario of mixed infections[4-6]. This is typical for 
instance in the field of pneumonia, whereby respiratory viruses and bacteria 
have often been described to act synergistically in the clinical syndrome they 
can both individually cause[7]. Similarly, among pediatric P. falciparum malaria 
cases, secondary bacterial infections can frequently be detected, often 
triggering a more severe presentation and a poorer prognosis[8]. Additionally, 
clinical management algorithms based on the identification of signs and 
symptoms associated with determined conditions and/or the risk of severity and 
treatment recommendations resulting from them, have been designed to prime 
sensitivity over specificity, and as a result, tend to overdiagnose antibiotic-
requiring conditions, leading to an exaggerated prescription of these drugs. 
While this approach is generally considered acceptable, due to the fact that it 
has shown (particularly in children) to contribute to improved survival[9], it does 
entail obvious deleterious consequences in relation to antimicrobial misuse and 
resistance, a major global health concern in the 21st century.  
In recent times, research on diagnostic biomarkers, one of the most active fields 
in diagnostic medicine, has focused on identifying proteins (mostly host-
response ones) capable of distinguishing between bacterial and viral infections, 
and therefore, indicative of the need to provide or withdraw antibiotics. This 
search of such “diagnostic holy grail” has been hampered by the poor reliability 
of most of the candidate biomarkers, their variation in performance in the light of 
co-existing conditions (such as for instance malaria, or HIV infection)[10], or the 
wide variability of their results in relation to the severity and magnitude of the 
infection. Although some of these proteins have been widely adopted in 
emergency rooms of Western hospitals for the rapid assessment of patients, a 
robust and reliably performing biomarker that could be universally used for this 
purpose among all age groups and in all settings, is far from a reality. This has 
paved the way to the investigation of prognostic (as opposed to “diagnostic”) 
biomarkers, i.e those that could reliably stratify risk of adverse outcomes, 












In this issue of the Clinical Infectious Diseases journal, Melissa Richard-
Greenblatt and colleagues assessed, among a series of 507 febrile adult 
Tanzanian patients (age range 23-49 years) which included 32 deaths, the 
prognostic ability of a panel of 11 host-response biomarkers of endothelial 
activation and immune dysfunction, previously hypothesized to be adequate 
and “etiology-agnostic” predictors of disease severity and mortality, when 
measured at clinical presentation [11]. They also assessed procalcitonin (PCT) 
and C-reactive protein (CRP), two well-known acute phase proteins routinely 
used in emergency departments for risk-stratification and management 
decisions in high-income countries, and a variety of widely utilized clinical 
severity scores, including qSOFA (quick Sepsis Related Organ Failure 
Assessment), SOFA (a modified version of it adjusted to LMIC settings), SIRS 
(Systemic Inflammatory Response Syndrome) clinical criteria, and the Glasgow 
Coma Scale (GCS). Of all markers assessed, STREM-1 (soluble triggering 
receptor expressed on myeloid cells-1, a protein member of a family of cell 
surface receptors, functioning as modulators of the inflammatory response in 
sepsis) seemed to have the best prognostic accuracy (AUROC 0.87, 95% CI 
0.81-0.92) for predicting day 28 mortality, clearly outperforming the two 
reference markers (PCT and CRP), and superior or similar to some validated 
clinical scoring systems on their own. Interestingly, the addition of STREM-1 to 
those scoring systems seemed to further enhance their prognostic accuracy. 
Importantly, STREM-1 retained its prognostic abilities irrespective of the 
underlying etiology (viral vs. bacterial), a finding that further supports the theory 
that pathways in which this biomarker is elevated are common to a variety of 
different infectious pathogens and can therefore be truly considered a harbinger 
of life-threatening disease. 
The implications of this study are notable. First, these results substantiate 
previous work describing the prognostic performance of specific host 
biomarkers of the endothelial activation and immune dysfunction pathways in 
sick children and adults, further corroborating their predictive importance not 
only for specific diseases (such as malaria[12], or sepsis[13, 14] for instance), 
but also for the much wider “fever syndrome”[15]. Second, these results 











risk-stratification, rather than on pathogen-family identification. Indeed, 
detecting those patients who do not necessarily appear severely ill but do have 
an objective measurement that is highly suggestive of an adverse outcome 
certainly provides more actionable information than just identifying whether the 
underlying etiology requires antimicrobials or not, particularly at the peripheral 
health system level, where a wrong decision can have profound implications in 
the likelihood of survival. Finally, the clear identification of one or more markers 
consistently associated with severity progression, sets a standard upon which 
designing new point of care (POC) tests based on their measurement in plasma, 
so as to assist clinicians in their assessment and decision-making processes. 
Such POC tests should be, ideally, deployable at the peripheral health system 
level, electricity-independent, rapid (providing results within minutes), qualitative 
of semi-quantitative (i.e suggesting two or three possible scenarios, such as “No 
risk”, “Moderate risk” or “high risk”), stable and providing reproducible results, 
and of sufficient low-cost so as to be implemented at a large scale, particularly 
in those settings where other diagnostic tools are scarce. The addition of such 
prognostic tools to already existing clinical algorithms could enhance those 
already in place, while providing an objective measurement upon which basing 
critical management decisions.  
Conceptually, such triaging tools could also be utilized in other clinical scenarios, 
where important management decisions need to take place, such as for 
example when deciding transfer of patients to a higher-level facility, when 
planning a switch from a parenteral treatment to an oral one, or at the moment 
of discharge, when anticipating the post-discharge mortality risk is not always 
easy, constituting a new paradigm shift in terms of outcome prediction. In this 
respect, and before any further development in this area, it would appear 
important to design a comprehensive clinical development plan consisting on a 
series of well-designed prospective randomized control trials, using biomarker 
levels on arrival as the key element in which to base therapeutic and 
management decisions, with disease severity and mortality as endpoints. This 
will teach us whether their real-life utilization does have the same impact that 


























1. Maze MJ, Bassat Q, Feasey NA, Mandomando I, Musicha P, Crump JA. The 
epidemiology of febrile illness in sub-Saharan Africa: implications for 
diagnosis and management. Clinical microbiology and infection : the official 
publication of the European Society of Clinical Microbiology and Infectious 
Diseases 2018. 
2. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. The Cochrane 
database of systematic reviews 2013; (11): Cd000023. 
3. Hazir T, Nisar YB, Abbasi S, et al. Comparison of oral amoxicillin with 
placebo for the treatment of world health organization-defined nonsevere 
pneumonia in children aged 2-59 months: a multicenter, double-blind, 
randomized, placebo-controlled trial in pakistan. Clin Infect Dis 2011; 
52(3): 293-300. 
4. Benet T, Sanchez Picot V, Messaoudi M, et al. Microorganisms Associated 
With Pneumonia in Children <5 Years of Age in Developing and Emerging 
Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control 
Study. Clin Infect Dis 2017; 65(4): 604-12. 
5. D'Acremont V, Kilowoko M, Kyungu E, et al. Beyond malaria--causes of fever 
in outpatient Tanzanian children. N Engl J Med 2014; 370(9): 809-17. 
6. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of 
diarrhoeal disease in infants and young children in developing countries 
(the Global Enteric Multicenter Study, GEMS): a prospective, case-control 
study. Lancet 2013; 382(9888): 209-22. 
7. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-
to-bedside review: bacterial pneumonia with influenza - pathogenesis and 
clinical implications. Critical care (London, England) 2010; 14(2): 219. 
8. Bassat Q, Guinovart C, Sigauque B, et al. Severe malaria and concomitant 
bacteraemia in children admitted to a rural Mozambican hospital. Trop Med 
Int Health 2009. 
9. Gera T, Shah D, Garner P, Richardson M, Sachdev HS. Integrated 
management of childhood illness (IMCI) strategy for children under five. 
The Cochrane database of systematic reviews 2016; (6): Cd010123. 
10. Diez-Padrisa N, Bassat Q, Machevo S, et al. Procalcitonin and C-reactive 
protein for invasive bacterial pneumonia diagnosis among children in 
Mozambique, a malaria-endemic area. PLoS ONE 2010; 5(10): e13226. 
11. Richard-Greenblatt, et al. Prognostic accuracy of sTREM-1-based algorithms 
in febrile adults presenting to Tanzanian outpatient clinics; In this issue. 
12. Conroy AL, Hawkes M, McDonald CR, et al. Host Biomarkers Are Associated 
With Response to Therapy and Long-Term Mortality in Pediatric Severe 
Malaria. Open forum infectious diseases 2016; 3(3): ofw134. 
13. Su L, Liu D, Chai W, Liu D, Long Y. Role of sTREM-1 in predicting mortality 
of infection: a systematic review and meta-analysis. BMJ open 2016; 6(5): 
e010314. 
14. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of 
endothelial activation in sepsis--a systematic review. Critical care (London, 











15. McDonald CR, Weckman A, Richard-Greenblatt M, Leligdowicz A, Kain KC. 
Integrated fever management: disease severity markers to triage children 







uique Bassat on 18 M
ay 2019
